Peter A Kaufman

Summary

Affiliation: Dartmouth-Hitchcock Medical Center
Country: USA

Publications

  1. doi request reprint Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane
    Peter A Kaufman
    Peter A Kaufman, Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, NH Edith A Perez, Mayo Clinic, Jacksonville, FL Martin S Olivo, Yi He, and Corina E Dutcus, Eisai, Woodcliff Lake, NJ Ahmad Awada, Medical Oncology Clinic, Jules Bordet Institute, Universite Libre de Bruxelles, Brussels, Belgium Chris Twelves and Galina Velikova, Leeds Institute of Cancer and Pathology, and St James s Institute of Oncology, Leeds, United Kingdom Louise Yelle, University of Montreal, Montreal, Quebec, Canada and Javier Cortes, Vall D Hebron University Institute of Oncology, Barcelona, Spain
    J Clin Oncol 33:594-601. 2015
  2. pmc The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
    Debu Tripathy
    Keck School of Medicine, University of Southern California, USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA
    BMC Cancer 14:307. 2014
  3. pmc Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study
    Peter A Kaufman
    Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
    Breast Cancer Res Treat 135:875-83. 2012
  4. pmc HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial
    Edith A Perez
    Serene M and Frances C Durling Professor of Medicine, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    J Clin Oncol 28:4307-15. 2010
  5. pmc Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial
    Edith A Perez
    Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    J Clin Oncol 31:2115-22. 2013
  6. pmc Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial
    Edith A Perez
    Division of Hematology Oncology, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    J Clin Oncol 26:1231-8. 2008
  7. pmc Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer
    Edith A Perez
    Mayo Clinic, Jacksonville, FL 32224, USA
    J Clin Oncol 29:4491-7. 2011
  8. pmc Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31
    Edith A Perez
    Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    J Clin Oncol 29:3366-73. 2011
  9. pmc Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831
    Alvaro Moreno-Aspitia
    Division of Hematology Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
    Cancer 119:2675-82. 2013
  10. pmc C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial
    Edith A Perez
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 29:651-9. 2011

Collaborators

Detail Information

Publications17

  1. doi request reprint Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane
    Peter A Kaufman
    Peter A Kaufman, Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, NH Edith A Perez, Mayo Clinic, Jacksonville, FL Martin S Olivo, Yi He, and Corina E Dutcus, Eisai, Woodcliff Lake, NJ Ahmad Awada, Medical Oncology Clinic, Jules Bordet Institute, Universite Libre de Bruxelles, Brussels, Belgium Chris Twelves and Galina Velikova, Leeds Institute of Cancer and Pathology, and St James s Institute of Oncology, Leeds, United Kingdom Louise Yelle, University of Montreal, Montreal, Quebec, Canada and Javier Cortes, Vall D Hebron University Institute of Oncology, Barcelona, Spain
    J Clin Oncol 33:594-601. 2015
    ..This phase III randomized trial (ClinicalTrials.gov identifier: NCT00337103) compared eribulin with capecitabine in patients with locally advanced or metastatic breast cancer (MBC)...
  2. pmc The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
    Debu Tripathy
    Keck School of Medicine, University of Southern California, USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA
    BMC Cancer 14:307. 2014
    ....
  3. pmc Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study
    Peter A Kaufman
    Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
    Breast Cancer Res Treat 135:875-83. 2012
    ..These real-world data suggest improved PFS across all age groups and similar trends for OS...
  4. pmc HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial
    Edith A Perez
    Serene M and Frances C Durling Professor of Medicine, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    J Clin Oncol 28:4307-15. 2010
    ....
  5. pmc Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial
    Edith A Perez
    Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    J Clin Oncol 31:2115-22. 2013
    ....
  6. pmc Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial
    Edith A Perez
    Division of Hematology Oncology, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    J Clin Oncol 26:1231-8. 2008
    ..To assess cardiac safety and potential cardiac risk factors associated with trastuzumab in the NCCTG N9831 Intergroup adjuvant breast cancer trial...
  7. pmc Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer
    Edith A Perez
    Mayo Clinic, Jacksonville, FL 32224, USA
    J Clin Oncol 29:4491-7. 2011
    ....
  8. pmc Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31
    Edith A Perez
    Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    J Clin Oncol 29:3366-73. 2011
    ..Long-term follow-up results on disease-free survival (DFS) and overall survival (OS) have been awaited...
  9. pmc Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831
    Alvaro Moreno-Aspitia
    Division of Hematology Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
    Cancer 119:2675-82. 2013
    ..In this study, the authors evaluated levels of sHER2 during treatment and at the time of disease recurrence in the adjuvant North Central Cancer Treatment Group N9831 clinical trial...
  10. pmc C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial
    Edith A Perez
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 29:651-9. 2011
    ....
  11. ncbi request reprint HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial
    Edith A Perez
    Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    J Clin Oncol 24:3032-8. 2006
    ..To evaluate concordance between local and central laboratory HER2 testing results in patients from the North Central Cancer Treatment Group (NCCTG) N9831 adjuvant trial of trastuzumab...
  12. pmc Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831
    Amylou C Dueck
    Authors Affiliations Section of Biostatistics Division of Anatomic Pathology, Mayo Clinic, Scottsdale, Arizona Division of Experimental Pathology, Department of Laboratory Medicine and Pathology Division of Biomedical Statistics and Informatics and Medical Oncology, Mayo Clinic, Rochester, Minnesota Division of Anatomic Pathology and Hematology Oncology, Mayo Clinic, Jacksonville, Florida Division of Hematology Oncology, University of Pittsburgh Cancer Institute and UPMC Cancer Center, Pittsburgh, Pennsylvania The Angeles Clinic and Research Institute, Santa Monica, California Indiana University Medical Center Cancer Pavilion, Indianapolis, Indiana Division of Hematology Oncology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire Oncology Associates of Cedar Rapids, Cedar Rapids, Iowa Seattle Cancer Care Alliance, Seattle, Washington and Case Western Reserve University, Cleveland, Ohio
    Clin Cancer Res 19:5798-807. 2013
    ....
  13. ncbi request reprint Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial
    Edith A Perez
    North Central Cancer Treatment Group, Division of Hematology Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
    J Clin Oncol 22:3700-4. 2004
    ....
  14. pmc Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: the impact of APOE and smoking
    Tim A Ahles
    Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA Department of Psychiatry and Center for Psycho Oncology Research, The Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA
    Psychooncology 23:1382-90. 2014
    ..This study examined the association of post-treatment changes in cognitive performance, apolipoprotein E (APOE), and smoking in breast cancer patients treated with adjuvant therapy...
  15. pmc Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer
    Peter A Kaufman
    Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire
    Cancer 120:2657-64. 2014
    ..The importance of human epidermal growth factor receptor 2 (HER2) as a prognostic and predictive marker in invasive breast cancer is well established. Accurate assessment of HER2 status is essential to determine optimal treatment options...
  16. pmc Cognitive function in breast cancer patients prior to adjuvant treatment
    Tim A Ahles
    Department of Psychiatry and Center for Psycho Oncology, The Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center Lebanon, Lebanon, NH, USA
    Breast Cancer Res Treat 110:143-52. 2008
    ..To compare the neuropsychological functioning of breast cancer patients with invasive cancer and noninvasive cancer prior to adjuvant treatment...
  17. ncbi request reprint The pharmacokinetics of the bispecific antibody MDX-H210 when combined with interferon gamma-1b in a multiple-dose phase I study in patients with advanced cancer
    Lionel D Lewis
    Department of Medicine, Dartmouth Medical School and the Norris Cotton Cancer Center, Lebanon, NH 03756, USA
    Cancer Chemother Pharmacol 49:375-84. 2002
    ..MDX-H210 is a Fab'xFab' bispecific antibody (BsAb) constructed chemically by crosslinking Fab' mAb 520C9 (anti-HER-2/neu) and humanized Fab' mAbH22 (anti-CD64)...